Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | ASC61 |
Synonyms | |
Therapy Description |
ASC61 inhibits CD274 (PD-L1), which potentially results in decreased tumor growth (Cancer Res 2022;82(12_Suppl):Abstract nr 5529). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ASC61 | ASC-61|ASC 61 | PD-L1 Inhibitor 13 | ASC61 inhibits CD274 (PD-L1), which potentially results in decreased tumor growth (Cancer Res 2022;82(12_Suppl):Abstract nr 5529). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05287399 | Phase I | ASC61 | Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASC61in Subjects With Advanced Solid Tumors | Recruiting | USA | 0 |